EMA Evaluates the Use of Kineret in Adult COVID-19 Patients

The European Medicines Agency (EMA) has begun reviewing Sobi’s Kineret (anakinra) for treating COVID-19 in adult pneumonia patients at risk of severe respiratory failure.

Kineret, an immunosuppressant drug first authorized in the EU in 2002, is meant to stop coronavirus-related inflammation and tissue damage by halting the activity of the interleukin 1 proteins.

The EMA’s human medicines committee is assessing data from two clinical trials and is expected to reach a decision by October, unless more information is required.